EE200100146A - Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine - Google Patents

Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine

Info

Publication number
EE200100146A
EE200100146A EEP200100146A EEP200100146A EE200100146A EE 200100146 A EE200100146 A EE 200100146A EE P200100146 A EEP200100146 A EE P200100146A EE P200100146 A EEP200100146 A EE P200100146A EE 200100146 A EE200100146 A EE 200100146A
Authority
EE
Estonia
Prior art keywords
alpha
subunit integrin
subunit
integrin
multiple myeloma
Prior art date
Application number
EEP200100146A
Other languages
English (en)
Inventor
R. Mundy Gregory
Yoneda Toshiyuki
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of EE200100146A publication Critical patent/EE200100146A/et
Publication of EE05558B1 publication Critical patent/EE05558B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
EEP200100146A 1998-09-14 1999-09-13 Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks EE05558B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (2)

Publication Number Publication Date
EE200100146A true EE200100146A (et) 2002-06-17
EE05558B1 EE05558B1 (et) 2012-08-15

Family

ID=22278506

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100146A EE05558B1 (et) 1998-09-14 1999-09-13 Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks

Country Status (28)

Country Link
US (1) US7211252B2 (et)
EP (2) EP1113810B1 (et)
JP (3) JP2002524529A (et)
KR (1) KR100628818B1 (et)
CN (1) CN1236815C (et)
AT (1) ATE418999T1 (et)
AU (1) AU757873B2 (et)
BR (1) BR9913705A (et)
CA (1) CA2343579C (et)
CY (1) CY1109413T1 (et)
CZ (1) CZ302997B6 (et)
DE (1) DE69940206D1 (et)
DK (1) DK1113810T3 (et)
EA (1) EA004270B1 (et)
EE (1) EE05558B1 (et)
ES (1) ES2319831T3 (et)
HU (1) HU229038B1 (et)
IL (2) IL141877A0 (et)
IS (1) IS2631B (et)
NO (2) NO327855B1 (et)
NZ (1) NZ511062A (et)
PL (1) PL203114B1 (et)
PT (1) PT1113810E (et)
SI (1) SI1113810T1 (et)
SK (1) SK287601B6 (et)
TR (1) TR200100734T2 (et)
WO (1) WO2000015247A2 (et)
ZA (1) ZA200102032B (et)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP1214091B1 (en) * 1999-09-14 2006-05-10 Biogen Idec MA Inc. Therapies for chronic renal failure using one or more integrin antagonists
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2003019136A2 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
WO2005076843A2 (en) * 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
US8808698B2 (en) * 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3461499A1 (en) * 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA021967B1 (ru) * 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
ES2912934T3 (es) * 2010-04-16 2022-05-30 Biogen Ma Inc Anticuerpos anti VLA-4
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AU2012277185A1 (en) * 2011-06-30 2014-02-13 Gene Techno Science Co., Ltd. Soluble integrin alpha4 mutant
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
JPH07506566A (ja) 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
USRE40811E1 (en) 1992-11-13 2009-06-30 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
EP0677060A1 (en) 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
DE69535133T2 (de) * 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
DK1082302T3 (da) * 1998-05-28 2004-04-26 Biogen Inc En VLA-4-inhibitor: oMePUPA-V
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
SK287601B6 (sk) 2011-03-04
ZA200102032B (en) 2002-11-07
HU229038B1 (hu) 2013-07-29
ES2319831T3 (es) 2009-05-12
NZ511062A (en) 2003-04-29
EA200100362A1 (ru) 2001-12-24
CA2343579C (en) 2012-05-29
WO2000015247A8 (en) 2009-12-23
JP2013241441A (ja) 2013-12-05
CZ302997B6 (cs) 2012-02-15
CY1109413T1 (el) 2014-08-13
CN1321091A (zh) 2001-11-07
KR100628818B1 (ko) 2006-09-27
EP1113810B1 (en) 2008-12-31
EA004270B1 (ru) 2004-02-26
NO20011283D0 (no) 2001-03-14
NO327855B1 (no) 2009-10-05
NO20011244L (no) 2001-05-14
SK6052001A3 (en) 2001-12-03
CZ2001916A3 (cs) 2001-08-15
KR20010085793A (ko) 2001-09-07
EP2065050A1 (en) 2009-06-03
AU6248699A (en) 2000-04-03
WO2000015247A2 (en) 2000-03-23
JP5378303B2 (ja) 2013-12-25
US20020022028A1 (en) 2002-02-21
EP1113810A2 (en) 2001-07-11
AU757873B2 (en) 2003-03-06
JP2002524529A (ja) 2002-08-06
PT1113810E (pt) 2009-03-10
ATE418999T1 (de) 2009-01-15
JP2010235620A (ja) 2010-10-21
NO20011244D0 (no) 2001-03-12
CN1236815C (zh) 2006-01-18
CA2343579A1 (en) 2000-03-23
WO2000015247A3 (en) 2000-05-25
IS5856A (is) 2001-02-23
DE69940206D1 (de) 2009-02-12
PL203114B1 (pl) 2009-08-31
IS2631B (is) 2010-06-15
PL347128A1 (en) 2002-03-25
IL141877A0 (en) 2002-03-10
HUP0103630A3 (en) 2004-03-01
TR200100734T2 (tr) 2001-07-23
IL197686A0 (en) 2011-07-31
BR9913705A (pt) 2001-06-05
EE05558B1 (et) 2012-08-15
SI1113810T1 (sl) 2009-04-30
US7211252B2 (en) 2007-05-01
HK1038313A1 (en) 2002-03-15
HUP0103630A2 (hu) 2002-01-28
DK1113810T3 (da) 2009-04-06

Similar Documents

Publication Publication Date Title
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
DE60038239D1 (de) Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie
BR0007875A (pt) Uso de um antagonista de integrina para inibir crescimento de tumor cerebral
ES2105408T3 (es) Piridilmetilpiridonas sustituidas como antagonistas de angiotensina ii.
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
TR199701356A2 (xx) L�kozit adhasyonu inhibit�rleri ve VLA-4-antagonistleri olarak heterosiklenler.
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
ATE234812T1 (de) Integrin antagonisten
BR0009767A (pt) Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
NO2019032I1 (no) Treosulfan
EP0635263A3 (en) Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DE60033416D1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
EP2236619A3 (en) BCL2L12 polypeptide activators and inhibitors
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
ATE280156T1 (de) Phthalimido arylpiperazinen als alpha 1a rezeptor antagonisten nützlich zur behandlung von gutartigen prostatahyperplasia
DK1194158T3 (da) Anvendelse af UK 114-proteiner til hæmning af organtransplantatafstödning
ECSP961901A (es) Compuestos de imidazolidin 2,4- diona sustituida
ITRM940091A0 (it) Procedimento per la preparazione di colture cellulari di eisenia foetida (anellidi, oligocheti).
MX9302324A (es) Antagonistas de endotelina ii.
ATE446099T1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69926997D1 (de) Blutverträgliche zusammensetzung und medizinische vorrichtung unter verwendung derselben

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20150913